Treatment of Aplastic Anemia with Antilymphocyte Globulin, High-dose Methylprednisolone and Androgen.

DOI Web Site PubMed
  • KOJIMA Seiji
    Division of Hematology/Oncology, Children's Medical Center, The Japanese Red Cross Nagoya First Hospital
  • MIYAJIMA Yuji
    Division of Hematology/Oncology, Children's Medical Center, The Japanese Red Cross Nagoya First Hospital
  • FUKUDA Minoru
    Division of Hematology/Oncology, Children's Medical Center, The Japanese Red Cross Nagoya First Hospital
  • MATSUYAMA Takaharu
    Division of Hematology/Oncology, Children's Medical Center, The Japanese Red Cross Nagoya First Hospital
  • MAEDA Hiroshi
    Department of Internal Medicine, The Japanese Red Cross Nagoya First Hospital
  • YAMAMOTO Kazuhito
    Department of Internal Medicine, The Japanese Red Cross Nagoya First Hospital
  • TSUZUKI Shinobu
    Department of Internal Medicine, The Japanese Red Cross Nagoya First Hospital
  • AKATSUKA Miki
    Department of Internal Medicine, The Japanese Red Cross Nagoya First Hospital
  • SUGIHARA Takuro
    Department of Internal Medicine, The Japanese Red Cross Nagoya First Hospital
  • MINAMI Saburo
    Department of Internal Medicine, The Japanese Red Cross Nagoya First Hospital
  • KODERA Yoshihisa
    Department of Internal Medicine, The Japanese Red Cross Nagoya First Hospital

Bibliographic Information

Other Title
  • 再生不良性貧血に対する抗リンパ球グロブリン，メチルプレドニゾロン大量，蛋白同化ホルモン併用療法
  • サイセイ フリョウセイ ヒンケツ ニ タイスル コウ リンパキュウ グロブリン

Search this article

Abstract

Twenty-seven patients with aplastic anemia (20 severe: 7 moderate) were treated with combined immunosuppression consisting of antilymphocyte globulin (ALG: Ahlbulin, Green Cross Co., Osaka, Japan) and high-dose methylprednisolone. Danazol or meptiostane was administered concurrently for at least 3 months. Ten of 27 patients had sustained improvement in hematopoiesis within 3 months of treatment. Three patients with hematological response had a recurrence of pancytopenia 12∼36 months after the combined immunosuppressive therapy. Six patients died due to fungal pneumonia (2), hepatic failure (2), interstitial pneumonitis (1) and complication following allogeneic bone marrow transplantation (1). By life table analysis, the survival rate for all patients was 76±8% at 4 years, with 70±10% survival rate for patients with severe aplastic anemia and 100% for patients with moderate aplastic anemia. The factors predicting the good response to the therapy were a longer interval from diagnosis to the therepy and higher counts of platelet and reticulocyte at admission.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 33 (1), 11-16, 1992

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top